CTI BioPharma: Lead candidate pacritinib, oral kinase inhibitor w specificity for JAK2, FLT3, IRAK1, and CSF1R in Ph 2 for treatment of myelofibrosis. Upcoming catalysts: pacritinib PAC203 Ph 2 data - mid'19, initiation of ph3 - Q3.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase III, Phase l or ll
Disease Space
Fibrosis, Hematology, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Small Molecule
Website:
Address:
3101 Western Ave
800
Seattle, WA 98121
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.